Recently, it was reported that ExoLab Italia, an Italian biotech startup specializing in the development of exosome-based products and applications, announced that it has raised €5 million (approximately ¥379.2 billion) in its Series A financing round. The round was backed by four investment funds: dsm-firmenich Ventures, CDP Venture Capital Sgr (through joint investments from Fondo Acceleratori and Fondo Italia Venture II – Linfa Fund, managed by Riello Investimenti Sgr), and Maia Ventures.
According to reports, with the support of new investors, ExoLab Italia plans to optimize its production processes and relocate from its current 300-square-meter research and production laboratory to a new facility in L’Aquila, Italy, spanning over 1,000 square meters. This move is considered a critical step toward the company’s goal of becoming the global leader in plant-derived exosome ingredient production. The expansion will not only enhance production capacity but also open new opportunities for advanced research projects.
Public records show that ExoLab Italia was founded in 2020 by Mariantonia Logozzi (Chief Technology Officer) and Stefano Fais (Scientific Director). The company aims to develop applications for plant-derived exosomes—cellular vesicles obtained from fruits that can enhance the efficacy of traditional active ingredients—in cosmetics, pharmaceuticals, and nutritional supplements. The concept stems from leveraging Italy’s rich organic agriculture resources and transforming them into a field of scientific discovery. With proprietary technology and advanced R&D initiatives, ExoLab Italia has become a leader in the innovation of natural functional active substances.
ExoLab Italia’s CEO stated, “The funds raised will enable us to implement an ambitious strategic plan, including industrial-scale expansion, internationalization, and key investments in human and capital resources.”
